High fat diet disrupts metabolism and increases disease risk
May 28, 2025 / high-fat diet metabolism / insulin resistance risk / reactive oxygen species damage / metabolic enzyme dysregulation / antioxidant therapy benefits
MIT researchers found high-fat diets disrupt metabolic enzyme activity, increasing insulin resistance and reactive oxygen species. These harmful effects, more severe in males, were largely reversible with antioxidant treatment, offering insight into diet-induced metabolic disease mechanisms and potential interventions.
Inhibition of serotonin-Htr2b signaling in skeletal muscle mitigates obesity-induced insulin resistance
June 2, 2025 / serotonin Htr2b inhibition / skeletal muscle insulin resistance / obesity metabolic health / AKT AMPK phosphorylation / type 2 diabetes therapy
Inhibiting serotonin-Htr2b signaling in skeletal muscle improves insulin sensitivity, glucose uptake, and energy metabolism in obesity. Targeting this pathway may offer a novel therapeutic strategy for treating insulin resistance and metabolic disorders like type 2 diabetes.
Newly discovered mechanism of mitochondrial dysfunction in obesity may drive insulin resistance and type 2 diabetes
May 30, 2025 / coenzyme Q metabolism / mitochondrial ROS obesity / liver dysfunction diabetes / reverse electron transport / type 2 diabetes mechanism
Harvard researchers identified dysregulated hepatic coenzyme Q metabolism as a key driver of mitochondrial ROS overproduction in obesity, linking it to insulin resistance and type 2 diabetes. This discovery enables targeted therapies over broad-spectrum antioxidant approaches in metabolic disease.
Childhood Obesity and Its Correlation With Vitamin D: A Systematic Review
May 29, 2025 / childhood obesity vitamin D / pediatric metabolic health / vitamin D deficiency children / obesity insulin resistance / pediatric nutrition screening
A systematic review reveals a moderate inverse correlation between vitamin D deficiency and childhood obesity, suggesting vitamin D’s potential role in metabolism, insulin sensitivity, and obesity-related disorders—highlighting the need for screening and tailored nutritional interventions in pediatric populations.
Anti-Malaria Medicine May Offer Alternative to Common Weight Loss Drugs
May 29, 2024 / halofuginone weight loss / GDF15 FGF21 metabolism / herbal obesity treatment / anti-malaria drug obesity / Changshan metabolic health
Halofuginone, derived from traditional anti-malaria herb Changshan, promotes weight loss by increasing GDF15 and FGF21 levels—reducing appetite and boosting metabolism. This dual-action mechanism positions HF as a promising, cost-effective alternative to current obesity treatments in preclinical models.
Leading health organizations release guidance on nutrition support for GLP-1 obesity therapies
May 31, 2025 / GLP-1 obesity therapy / nutrition support guidelines / obesity lifestyle medicine / micronutrient deficiency GLP-1 / GLP-1 weight management
Four major medical societies released unified guidance emphasizing evidence-based nutrition strategies to support patients on GLP-1 obesity therapies, aiming to enhance weight loss, preserve lean mass, mitigate side effects, and promote long-term metabolic health through integrative lifestyle care.
Scientists may have discovered why the pounds come back after losing weight
May 28, 2025 / metabolic memory obesity / fat cell weight regain / obesity relapse research / post-weight loss metabolism / weight loss inflammation
A new study suggests fat cells retain a “metabolic memory” of obesity, impairing metabolism and promoting weight regain even after weight loss, due to persistent inflammation, sugar dysregulation, and abnormal fat storage in formerly obese individuals.
Countering Obesity with Drugs Vs Viable Alternatives
May 31, 2025 / GLP-1 obesity drugs India / Mounjaro weight loss side effects / Wegovy India launch / sustainable obesity treatment / obesity pharmacotherapy guidelines
India’s rising obesity rates have fueled demand for GLP-1 drugs like Mounjaro and Wegovy, but experts urge caution due to side effects, rebound weight gain, and misuse—emphasizing the need for sustainable lifestyle changes and national prescribing guidelines.
Pregnant Women With MASLD Have Triple Preterm Birth Risk
June 2, 2025 / MASLD pregnancy risk / preterm birth fatty liver / MASLD maternal health / metabolic liver disease pregnancy / MASH and childbirth outcomes
Pregnant women with MASLD face a threefold increased risk of preterm birth, independent of obesity or liver disease severity, underscoring the need for targeted monitoring and updated clinical guidelines for maternal care in metabolic liver disease.
New liver disease tools help diagnose, treat older adults early
June 2, 2024 / MASLD liver screening / nonalcoholic fatty liver tools / older adult liver disease / early fibrosis detection / MASH liver diagnostics
New noninvasive tools like FibroScan and MRI-based diagnostics enable earlier detection of MASLD in older adults, helping to prevent progression to cirrhosis, liver failure, or cancer—conditions often overlooked due to the disease’s asymptomatic nature and long latency.
GLP-1 Receptor Agonists Linked to Cardiovascular and Renal Benefits Beyond Weight Loss
May 31, 2025 / GLP-1 cardiovascular benefits / semaglutide renal outcomes / tirzepatide beyond weight loss / MASH and CKD treatment / cardiometabolic therapy GLP-1
GLP-1 receptor agonists like semaglutide and tirzepatide offer cardiovascular and renal benefits beyond weight loss, improving lipid profiles, glycemic control, MASH, and chronic kidney disease outcomes—expanding their therapeutic value in managing cardiometabolic conditions.
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
May 28, 2025 / Akero Therapeutics MASH / efruxifermin Phase 3 trials / MASLD liver disease treatment / metabolic liver disease therapy / Jefferies Healthcare Conference 2025
Akero Therapeutics will present updates on its Phase 3 trials of efruxifermin (EFX) for MASH and MASLD at the Jefferies Global Healthcare Conference, highlighting its continued leadership in developing treatments for advanced metabolic liver diseases.
Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025
May 27, 2025 / PXL065 hypertrophic cardiomyopathy / Poxel ESC Congress 2025 / mitochondrial dysfunction HCM / pioglitazone derivative cardiac therapy / oxidative stress cardiac treatment
Poxel’s PXL065, a deuterium-stabilized pioglitazone R-enantiomer, demonstrated promising preclinical efficacy in hypertrophic cardiomyopathy by targeting mitochondrial dysfunction, oxidative stress, and fibrosis, and will be presented at the ESC Congress 2025.
Changes in metabolic syndrome status and risk of chronic kidney disease over a decade of follow-up in the Iranian population
May 30, 2025 / metabolic syndrome CKD risk / chronic kidney disease Iran study / MetS recovery kidney health / blood pressure triglyceride CKD / longitudinal MetS kidney outcomes
Persistent or newly developed metabolic syndrome significantly increases chronic kidney disease risk, while recovery from MetS lowers that risk compared to stable MetS. Key drivers include blood pressure, glucose, triglycerides, and central obesity changes over time.
Women and the Intersection of Heart, Kidney and Metabolic Health
June 2, 2025 / women heart kidney health / CKM syndrome awareness / menopause cardiovascular risk / pregnancy diabetes kidney disease / American Heart Association women>
Women face elevated, often underrecognized risks for cardiovascular, kidney, and metabolic diseases, especially influenced by diabetes, pregnancy complications, and menopause. Early intervention and awareness of CKM health connections are critical for prevention and long-term wellness.
Consider Sex of Both Parent and Child in MetS Screening
May 28, 2025 / parental metabolic syndrome / adolescent MetS risk / maternal vs paternal MetS / triglycerides in children / sex-specific metabolic screening
Parental metabolic syndrome (MetS) impacts children’s metabolic health differently by sex. Paternal MetS strongly affects boys, while maternal MetS influences triglyceride levels in both sexes. Screening and prevention strategies should consider both parent and child sex.
The first hidden sign of dementia that can appear 20 years before common symptoms
May 29, 2025 / ‘early dementia signs / spatial orientation and Alzheimer’s / dementia prevention strategies / metabolic syndrome dementia risk / Alzheimer’s early detection
Loss of spatial orientation may be an early dementia indicator, emerging up to 20 years before memory loss. Early brain changes target orientation cells, suggesting a critical window for detection and intervention before Alzheimer’s symptoms fully develop.
Women and the Intersection of Heart, Kidney and Metabolic Health
June 1, 2025 / women’s heart health / CKM syndrome risk / menopause and heart disease / pregnancy complications kidney risk / metabolic health in women
Women face heightened, often underrecognized risk for cardiovascular, kidney, and metabolic diseases, especially due to conditions like diabetes, menopause, and pregnancy complications. Early intervention and awareness of sex-specific symptoms are critical for improving long-term CKM (cardiovascular-kidney-metabolic) health outcomes.
Linoleic acid may help to lower risks for heart disease and type 2 diabetes
June 1, 2025 / Linoleic acid / Seed oils / Heart disease / Type 2 diabetes prevention
Higher blood levels of linoleic acid, an omega-6 fatty acid found in seed oils, are linked to reduced inflammation and lower cardiometabolic risk, suggesting potential protective effects against heart disease and type 2 diabetes despite common misconceptions.
Can omega-6 fatty acids in nuts, vegetable oils lower heart disease and diabetes risk?
June 1, 2025 / Omega-6 fatty acids / Linoleic acid / Cardiometabolic health / Diabetes prevention / Heart disease risk
Two new studies link higher blood levels of linoleic acid, an omega-6 fatty acid from nuts and vegetable oils, to improved cardiometabolic health and reduced risk of heart disease and type 2 diabetes through better inflammation and glucose regulation.